ライフサイエンスコーパス: pain relief

1 and hence may offer a new analgesic tool for pain relief.

2 ache by behavioral assessment of reward from pain relief.

3 mental organisations are improving access to pain relief.

4 rescued opioid responsiveness toward better pain relief.

5 to identify those most likely to experience pain relief.

6 nce the understanding of the biochemistry of pain relief.

7 egression analysis to estimate predictors of pain relief.

8 point was frequency and duration of complete pain relief.

9 resulted in clinically useful therapies for pain relief.

10 newborn infants should not be interpreted as pain relief.

11 ers to mediate completely different types of pain relief.

12 bitors such as celecoxib are widely used for pain relief.

13 1) is suggested as a therapeutic approach to pain relief.

14 ion while offering a novel, simple method of pain relief.

15 e in their use in children for postoperative pain relief.

16 cking neurotransmission, producing transient pain relief.

17 for chronic low back pain) are effective for pain relief.

18 k pain and may be efficacious for short-term pain relief.

19 pentin (for radiculopathy) are effective for pain relief.

20 resulting in attenuation of opioid-mediated pain relief.

21 hospital admissions, and providing prolonged pain relief.

22 satisfaction with the improved postoperative pain relief.

23 y induced pain can be conditioned to predict pain relief.

24 how humans learn to generate expectations of pain relief.

25 dose reduction whilst delivering significant pain relief.

26 ia, the presence of which was a criterion of pain relief.

27 s were pharmacokinetics, tumor response, and pain relief.

28 ore (CPPR-Score) as a tool for prediction of pain relief.

29 linesterase inhibitors can produce effective pain relief.

30 ural analgesia provides better postoperative pain relief.

31 ipheral metabotropic glutamate receptors for pain relief.

32 oups; all received opioids for postoperative pain relief.

33 uroma, surgical removal can produce dramatic pain relief.

34 tients obtained significant and long-lasting pain relief.

35 dosing may be preferable to ensure adequate pain relief.

36 creas have a higher likelihood of successful pain relief.

37 the dosage of naproxen without compromising pain relief.

38 be strong independent prognostic factors for pain relief.

39 ical muscarinic side effects and provides no pain relief.

40 ogy, in addition to its known involvement in pain relief.

41 hronic pancreatitis, especially in regard to pain relief.

42 ioid epidemic while simultaneously providing pain relief.

43 n endosomes provides an important target for pain relief.

44 e them attractive candidates for therapeutic pain relief.

45 bility of analgesics, including opioids, for pain relief.

46 its ligand, NGF, are in clinical trials for pain relief.

47 edicines is intrinsic to achieving effective pain relief.

48 t, such as harnessing endogenous opioids for pain relief.

49 to be treated primarily with analgesics for pain relief.

50 inuous pain were moderated by expectation of pain relief.

51 lly provide a novel therapeutic strategy for pain relief.

52 quired acute medical interventions for their pain relief.

53 alkaloids from the opium poppy are used for pain relief.

54 ronic and acute pain, and a novel target for pain relief.

55 uce anxiety and the need for post-procedural pain relief.

56 gnals conveyed by a treatment procedure into pain relief.

57 ur that may allow us to intervene to provide pain-relief.

58 to 93% versus 25% to 86% for any intrapartum pain relief, 19% to 83% versus 10% to 64% for epidural a

59 353 patients vs 33 [10%] of 343 [p<0.0001]), pain relief (194 [55%] of 353 vs 95 [28%] of 343 [p<0.00

60 Treatment resulted in clinically meaningful pain relief (57% of patients) and reduction or discontin

61 e is an effect supporting meditation-related pain relief above and beyond the effects of placebo.

62 e neurophysiological changes associated with pain relief acquired through the observation.

63 Specifically, mindfulness meditation-induced pain relief activated higher-order brain regions, includ

64 th 32P-orthophosphate, and the similarity in pain relief afforded by 32P-orthophosphate and 89Sr-chlo

65 Forty-three (91%) patients reported pain relief after injections.

66 ortantly, compound 2 produced dose-dependent pain relief after oral administration in CCI rats (ED(50

67 ndependent factor associated with successful pain relief after pancreatic resection.

68 The rate of pain relief after surgical treatment in chronic pancreat

69 nt was altered in three (37%) as a result of pain relief after the injections.

70 teen of these 21 patients achieved long-term pain relief after their second procedure.

71 are an analgesic option that offer improved pain relief among other benefits.

72 tic head resection, which may provide better pain relief among people who do not respond to endoscopi

73 sitive neurons and diminish cooling-mediated pain relief (analgesia).

74 5 months, all patients indicated significant pain relief and 76% were pain free.

75 l steroids (75%) reported 50% or greater leg pain relief and a positive global perceived effect at 1

76 he site of injury, with the hope of enhanced pain relief and a reduction in the side effects associat

77 n assessment; 2) administering narcotics for pain relief and benzodiazepines for anxiety relief; 3) a

78 Clinical outcomes, including pain relief and change in pain medication requirements,

79 are equally effective in providing long-term pain relief and decreasing disease-specific hospital-bas

80 that mindfulness meditation produces greater pain relief and employs distinct neural mechanisms than

81 and heroin, mediating their effects in both pain relief and euphoria.

82 This strategy has prolonged pain relief and facilitated major operations on an outpa

83 s differentially encodes values for expected pain relief and for expected monetary reward.

84 by nonsurgical treatment resulted in greater pain relief and functional improvement after 12 months t

85 ispanic patients in particular reported less pain relief and had less adequate analgesia.

86 or exercise therapy in providing short-term pain relief and improved physical function in patients w

87 islet autotransplantation provides sustained pain relief and improved quality of life.

88 gs indicate that tanezumab provides superior pain relief and improvement in physical function and pat

89 This operation produces durable pain relief and improvement in QOL parameters.

90 nd Frey procedure provide good and permanent pain relief and improvement of the quality of life in lo

91 patients with chronic pancreatitis provides pain relief and improves quality of life, but the effect

92 sential medications and supplies can provide pain relief and palliative care; however, the practical

93 ternative care delivery system could improve pain relief and reduce unnecessary hospital admissions f

94 low mortality and a good outcome in terms of pain relief and return to work in approximately 60% of p

95 response to treatment (child's assessment of pain relief and sense of improvement).

96 n be expected to lead to prominent and rapid pain relief and significant improvement of the patient's

97 We aimed to examine pain relief and the extent of spinal cord activation wit

98 rity of surgery vs endotherapy for long term pain relief and weight gain in painful chronic pancreati

99 ions previously implicated in expectancy for pain-relief and increased attention during treatment of

100 ients receiving ziconotide achieved complete pain relief, and 50.0% of patients receiving ziconotide

101 ch subject, were used to model patient mood, pain relief, and pain intensity scores at three times af

102 require hospitalization or surgery, provides pain relief, and significantly improves cartilage qualit

103 s simple, does not require surgery, provides pain relief, and significantly improves cartilage qualit

104 s simple, does not require surgery, provides pain relief, and significantly improves disc quality.

105 type of multipotent stromal cells, produces pain relief (antihyperalgesia) that lasts for months.

106 tanding how the receptor systems involved in pain relief are altered during acute or chronic pain, an

107 eatitis suggests that the best predictors of pain relief are an intermittent pattern of pain and the

108 that cognitive factors (e.g., expectation of pain relief) are capable of modulating physical and emot

109 We used number needed to treat (NNT) for 50% pain relief as a primary measure and assessed publicatio

110 seems to provide improvement in function and pain relief as an adjunctive therapy for osteoarthritis

111 n the middle- and high-dose cohorts reported pain relief as assessed by NRS and SF-MPQ.

112 nd physician evaluations were used to assess pain relief, as was concurrent change in opioid analgesi

113 or placebo were observed in all trials, with pain relief at 2 hours ranging from 53% to 57.5%.

114 ents in the morphine group failed to achieve pain relief at any time after the dose compared with tho

115 Complete or partial pain relief at end of follow-up was achieved in 23 of 40

116 Secondary outcomes were pain relief at the end of follow-up; number of intervent

117 Secondary end points included pain relief (at 2 hours), sustained pain relief (from 2

118 ined DH staff delivered prompt titration for pain relief based on each patient's analgesic history an

119 Can pain relief be provided while reducing negative conseque

120 ties, results in excellent to fair long-term pain relief, but approximately 10% of patients do not re

121 , topical NSAIDs are associated with greater pain relief, but are not associated with an increase in

122 drainage procedures often provide transient pain relief, but long-term recurrence is common due to t

123 It can provide pain relief by an opioid-independent mechanism.

124 exploitation of a novel mechanism providing pain relief by CB(1) inverse agonists.

125 portion of patients without heartburn by D7, pain relief by D7, and reduction in pain intensity by D7

126 CCK(2) receptor antagonists potentiate pain relief by MOP receptor agonists.

127 the Lancet Commission on Palliative Care and Pain Relief, by combining WHO mortality projections (201

128 ther a potential therapeutic candidate gives pain relief, by modulating central pain neurobiology, we

129 The duration of this pain relief can range from minutes to an indefinite peri

130 e anti-inflammatory properties of aspirin in pain-relief, cardio-protection, and chemoprevention are

131 rgical drainage provides sustained, superior pain relief compared with endoscopic treatment in patien

132 eceive ketorolac (Toradol) for postoperative pain relief compared with other analgesic agents.

133 et compounds, which induce markedly improved pain relief compared with the parent NSAIDs.

134 02) and pathologic fracture (P = .01), while pain relief correlated with pathologic fracture (P = .03

135 s compared with prednisone alone in terms of pain relief, delayed pain progression, and prevention of

136 ine patients (45%) and partial in six (30%); pain relief did not occur in five patients (25%).

137 he results demonstrate that meditation-based pain relief does not require endogenous opioids.

138 portion of patients who met the criteria for pain relief during the entire evaluation period was not

139 r blockade make them an excellent choice for pain relief during the first stage of labor.

140 ding light on the possibility to enhance the pain relief effect of CA inhibitors inserting a CO relea

141 tions were found for augmentation of labour, pain relief, episiotomy, instrumental birth, and cesarea

142 patients experiencing clinically significant pain relief), except in the case of tricyclic antidepres

143 l osteolytic metastases provides significant pain relief for cancer patients who have failed standard

144 remains the most effective, safe approach to pain relief for labor, and demand for its use continues

145 andard of care does not provide satisfactory pain relief for many patients.

146 of a proposed framework to improve access to pain relief for patients with cancer across the region.

147 f radiofrequency ablation (RFA) in providing pain relief for patients with refractory pain secondary

148 oid injections may provide modest short-term pain relief for some adults with lumbosacral radiculopat

149 with the promise of extensive postoperative pain relief for the ambulatory surgery patient.

150 s the hypothesis that DBS provides long-term pain relief for the majority of CCH patients.

151 that have the potential to provide improved pain relief for those many patients whose needs remain p

152 devices have raised the hope of opioid-free pain relief for virtually the entire duration of postsur

153 Postoperative pain relief (freedom from narcotic analgesics) was achie

154 ss than half of patients report satisfactory pain relief from current treatments.

155 ve neuropathic pain in humans who do not get pain relief from opioids.

156 ever, many patients fail to achieve adequate pain relief from these highly brain-penetrant drugs beca

157 sceral pain in chronic pancreatitis predicts pain relief from various treatments, but nonvisceral pai

158 n combination with alcohol ablation provided pain relief from visceral tumors in most patients with i

159 included pain relief (at 2 hours), sustained pain relief (from 2 to 24 hours), sustained freedom from

160 s Survey was used to assess expectations for pain relief, functional improvement, and psychological w

161 Outcomes were pain relief, functional improvement, and radiographic no

162 tamizol) were required to provide meaningful pain relief (>30%).

163 that experience 50% or greater self-reported pain relief, have stalled.

164 ys of supportive care are airway monitoring, pain relief, hydration, and control of nausea.

165 paired with saphenous nerve block to elicit pain relief (i.e., conditioned place preference, CPP), r

166 y was by far more likely to provide complete pain relief if administered before rather than after the

167 lity contained five subthemes; experience of pain relief, improvements in physical activity, relaxati

168 Celiac plexus block provides short-term pain relief in a subset of patients.

169 uscle relaxants are effective for short-term pain relief in acute low back pain but caused sedation.

170 recise estimates and predictors of long-term pain relief in an individual patient data meta-analysis.

171 studies have revealed that HBO2 can produce pain relief in animal models of chronic pain as well.

172 tter survival and symptom control (including pain relief in bone metastases) than those treated with

173 elevating EETs is a novel path to accomplish pain relief in both inflammatory and neuropathic pain st

174 ree-step analgesic ladder leads to effective pain relief in hemodialysis patients.

175 bic) versus a non exercise control group for pain relief in hip OA.

176 ncreased advocacy for the use of opioids for pain relief in infants.

177 Repeat doses are effective in providing pain relief in many patients.

178 d suggest potential treatment strategies for pain relief in MS.

179 Few options are available for pain relief in patients with bone metastases who fail st

180 kle-arthroplasty designs provide substantial pain relief in patients with end-stage ankle osteoarthri

181 thesized that tDCS treatment would result in pain relief in patients with fibromyalgia.

182 ent a novel therapeutic strategy for chronic pain relief in patients with LDH.

183 Although NCPB improves pain relief in patients with pancreatic cancer vs optimi

184 ion of NGX-4010 provided rapid and sustained pain relief in patients with postherpetic neuralgia.

185 patients, triptan therapy provides complete pain relief in some attacks but not in others.

186 It can provide excellent short-term pain relief in some patients, but reliable predictors of

187 The percentage of patients reporting pain relief in the first and second hours after drug adm

188 drugs) analgesic drugs can markedly enhance pain relief in the perioperative period.

189 n significantly impairs HRQOL, and effective pain relief in these patients significantly increases HR

190 Predictors of surgical pain relief include onset of symptoms less than 3 years

191 equally effective in facilitating long-term pain relief, increased activity level, and decreased ana

192 se results implicate opioid receptors in the pain relief induced by HBO2.

193 Systemic sumatriptan did not alter pain relief-induced CPP in rats with incisional injury.

194 Patients tell us that improved pain relief is a principal concern.

195 However, their effectiveness in pain relief is also highly debated and some adverse side

196 hich can be limited to the location at which pain relief is expected.

197 king pain intensity level as an indicator of pain relief is insufficient and can lead to misinterpret

198 Access to essential drugs for pain relief is limited by legal and regulatory restricti

199 irst to demonstrate that mindfulness-related pain relief is mechanistically distinct from placebo ana

200 asive and non-invasive brain stimulation for pain relief is not new.

201 must understand why development of drugs for pain relief is so challenging.

202 In the arena of chronic pancreatitis, pain relief is still the most common reason for surgical

203 Immediate postprocedural pain relief is the best predictor of midterm clinical ou

204 e and, in normal subjects, predicted reward (pain relief) magnitude at stimulus offset.

205 nergic inhibition is an important endogenous pain-relief mechanism which can be activated by local gl

206 ged in patients with cardiovascular disease, pain-relief medication is often required and, in the abs

207 c awareness, and gaps in access to essential pain-relief medicines.

208 h that the amount of drug required to elicit pain relief must be increased to compensate for diminish

209 In terms of the extent and time course of pain relief, NGF blockade also reduced pain 40% to 70%,

210 ain, pain-related functional impairment, and pain relief obtained by taking analgesic drugs.

211 Immediate pain relief of 100% was achieved in all patients.

212 , in a general population admitted for chest pain, relief of pain after nitroglycerin treatment does

213 targeting central sites may be required for pain relief once BTP has been initiated.

214 ome events gathered during annual follow-up: pain relief, onset of diabetes, body weight maintenance,

215 ding their perceived importance of providing pain relief or avoiding adverse drug effects may have im

216 percentage or larger volume leads to better pain relief or decreased pain (P > .05).

217 done was not associated with superior cancer pain relief or fewer adverse effects compared with other

218 five co-primary endpoints were pain freedom, pain relief, or absence of photophobia, phonophobia, or

219 (MR)-guided RFA and/or alcohol ablation for pain relief over a 2-year period were retrospectively id

220 Higher preference to provide pain relief (over avoid analgesic risk) lessened the lik

221 y artery disease, 41% (113 of 275) had chest pain relief (P > 0.2).

222 0.001), which was paralleled by significant pain relief (P < 0.001).

223 he unipediculate procedure achieved adequate pain relief (P =.65) with mean decreases in pain severit

224 roved to be a very good predictive score for pain-relief (P < 0.001).

225 ronic pancreatitis is beneficial in terms of pain relief, pancreatic function and quality of life, co

226 t phase, pain modulation and expectations of pain relief persisted to a larger degree in the treatmen

227 -the-clock medication.) Pain intensity (PI), pain relief (PR), and global satisfaction scores were re

228 e, parents completed surveys assessing their pain relief preference (i.e., their rated importance of

229 t is palliative, with the principle goals of pain relief, preservation of neurologic function, and im

230 er, a newly introduced bill in Congress, the Pain Relief Promotion Act of 1999 (PRPA), could dramatic

231 the effect of epidural analgesia and PCA on pain relief, pulmonary function, cathechol release, and

232 Outcome measures include functional (pain relief, quality of life [QoL]), medical (endo- and

233 f pain as recorded in a diary, the degree of pain relief, quality of life, psychological and cognitiv

234 Acute therapy includes complete pain relief, rehydration, and encouragement of diuresis.

235 preference (i.e., their rated importance of pain relief relative to adverse drug event avoidance), p

236 However, no significant difference in pain relief, ROM, or increased Knee Society Knee Functio

237 , we describe the novel Chronic Pancreatitis Pain Relief Score (CPPR-Score) as a tool for prediction

238 The Chronic Pancreatitis Pain Relief Score allows identifying patients who will b

239 agement by harnessing endogenous opioids for pain relief.SIGNIFICANCE STATEMENT The current prescript

240 Pain relief starts 1-4 weeks after the initiation of tre

241 tly less analgesic medication but had better pain relief than group 1 patients.

242 TDF provided significantly better pain relief than placebo, as demonstrated by the primary

243 atory drugs (NSAIDs) associated with greater pain relief than placebo, other drugs, and nondrug treat

244 ative in polarity, suggesting that the acute pain relieves the ongoing back pain.

245 nterest has focused on TRPV1 as a target for pain relief, the chronic blockade of this pain receptor

246 ight have been used for complication-related pain relief, the odds of complications associated with k

247 -based treatment has been the cornerstone of pain relief, the use of these drugs should be limited be

248 Phenomena such as placebo analgesia or pain relief through distraction highlight the powerful i

249 isingly few patients, and provide equivalent pain relief to 65% of selected patients.

250 suggests that hypnosis can provide temporary pain relief to the majority of individuals with chronic

251 s, or coxibs, designed to provide comparable pain relief to traditional nonsteroidal anti-inflammator

252 ents for neuropathic pain deliver inadequate pain relief, unacceptable side effects, or both.

253 antly greater and more clinically meaningful pain relief up to 12 months than open-loop spinal cord s

254 The methods of pain relief used or discussed include nonpharmacologic t

255 it neuroprotection and sustained neuropathic pain relief via TGF-beta1 secretion.

256 The mean duration of pain relief was 11.8 months after RFN, with a maximum av

257 The degree of pain relief was 3 in two patients and 4 in eight patient

258 Overall the rate of pain relief was 79.8% after surgery.

259 Long-term pain relief was achieved in 90%, and pseudocyst recurren

260 Pain relief was analysed post hoc.

261 As secondary measures, efficacy of pain relief was assessed using a numeric rating scale (N

262 Mindfulness-meditation-related pain relief was associated with greater activation in br

263 Complete or partial pain relief was attained in 60% and 70% of patients afte

264 Pain relief was categorized as complete, partial, minima

265 At study endpoint, pain relief was comparable among all lumiracoxib dosages

266 At 1-6-week follow-up, pain relief was complete in nine patients (45%) and part

267 Chest pain relief was defined as a decrease of at least 50% in

268 The degree of pain relief was evaluated by using subjective criteria,

269 Pain relief was excellent in 7% and good in 38% of child

270 The proportion of attacks for which pain relief was experienced at 15 min was 62.46% (95% CI

271 Pain relief was moderate to complete in 52.9% of patient

272 mg above the naproxen daily dosage at which pain relief was no longer adequate.

273 In 100% cases pain relief was observed immediately after the procedure

274 Pain relief was observed in 62% to 72% of those who rece

275 Pain relief was observed within 1 week of administration

276 Persistence of pain relief was seen through week 16 in 43% of patients

277 Pain relief was similar in both groups.

278 On D7, overall quality of pain relief was slightly in favour of omeprazole (p = 0.

279 For effective interventions, pain relief was small to moderate and generally short-te

280 Decreases in prostate-specific antigen and pain relief were noted in a patient subset.

281 alf, thereby achieving prolonged neuropathic pain relief while doubling the margin of safety against

282 Pain relief with 153Sm-EDTMP was 75%: 33.33% complete, 5

283 Pain relief with 177Lu-EDTMP was 80%: 50% complete, 41.6

284 Pain relief with adjunct means of pain modulation should

285 Pain relief with anesthetic injection helped confirm the

286 st cells and eosinophils) is associated with pain relief with defecation and with anxiety and depress

287 t cell density was higher in those reporting pain relief with defecation.

288 ed pharmaceuticals hold forth the promise of pain relief with improved side-effect profiles over curr

289 re similar in patients with or without chest pain relief with nitroglycerin (P > 0.2).

290 The belief that chest pain relief with nitroglycerin indicates the presence of

291 their chest pain, 35% (49 of 141) had chest pain relief with nitroglycerin.

292 ignificant impediments to achieving adequate pain relief with opioids.

293 Excellent pain relief with regional anesthesia is well demonstrate

294 Radioisotopes are effective in providing pain relief with response rates of between 40% and 95%.

295 he patients were titrated to relief; 90% had pain relief within 2 to 4 hours.

296 rons, such an approach might offer effective pain relief without a significant side-effect liability.

297 eroids are frequently used for postoperative pain relief without definite evidence.

298 ay serve an analgesic advantage in providing pain relief without promoting addiction.

299 ely lead to therapeutics designed to provide pain relief without the adverse side effects normally as

300 ng ankle-brachial index, toe-brachial index, pain relief, wound healing, or major amputation.